Sandbox: ATL

Revision as of 19:51, 24 January 2016 by Haytham Allaham (talk | contribs)
Jump to navigation Jump to search

[1][2][3]


prognosis

Clinical form age poor clinical performance status high lactate dehydrogenase (LDH) high β2‐microglobulin high leukemic counts hypercalcemia high serum level of CD25 high serum neuron‐specific enolase

Prognostic Factor Description
Age
  • Older age at the time of diagnosis is associated with a worse prognosis.
Gender
  • Males are associated with a worse prognosis when compared to females.
Performance status
Stage
  • Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
Lymphocyte doubling time
  • A rapid lymphocyte doubling time is associated with a worse prognosis.
Genetic mutations
Prolymphocytes percent
  • An increased percentage of prolymphocytes is associated with a worse prongnosis.
Histological analysis
Lactate dehydrogenase (LDH) level
  • Elevated level of LDH is associated with a worse prognosis.
β2-microglobulin level
  • Elevated level of β2-microglobulin level is associated with a worse prognosis.
Lymphocyte surface markers
  • Over expression of CD38 is associated with a worse prognosis.
Immunoglobulin (Ig)VH gene
  • The absence of IgVH gene mutation is associated with a worse prognosis.
Membrane-bound proteins
  • The expression of zeta-chain-associated protein kinase 70 (ZAP) is associated with a worse prognosis.
  1. Mahieux R, Gessain A (2007). "Adult T-cell leukemia/lymphoma and HTLV-1". Curr Hematol Malig Rep. 2 (4): 257–64. doi:10.1007/s11899-007-0035-x. PMID 20425378.
  2. Matutes E (2007). "Adult T-cell leukaemia/lymphoma". J Clin Pathol. 60 (12): 1373–7. doi:10.1136/jcp.2007.052456. PMC 2095573. PMID 18042693.
  3. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y; et al. (2015). "Treatment and survival among 1594 patients with ATL". Blood. 126 (24): 2570–7. doi:10.1182/blood-2015-03-632489. PMID 26361794.